Deerfield Management Company, L.P. (Series C) Cullinan Oncology, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,280,237 shares of CGEM stock, worth $58.9 Million. This represents 1.2% of its overall portfolio holdings.
Number of Shares
3,280,237
Previous 1,138,531
188.11%
Holding current value
$58.9 Million
Previous $19.4 Million
194.88%
% of portfolio
1.2%
Previous 0.4%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
140Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$137 Million21.42% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$103 Million3.07% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$63.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$61.3 Million15.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$51.5 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $819M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...